Literature DB >> 25201195

Mechanisms of mutant p53 stabilization in cancer.

Rebecca A Frum1, Steven R Grossman.   

Abstract

p53 transactivates cell cycle inhibitory, apoptosis or senescence-related genes in response to DNA damage to protect the genetic integrity of the cell. Highlighting its critical tumor suppressor functions, p53 is mutated, lost, or functionally inactivated in nearly all cancers. When mutated within its core DNA binding domain, p53's normal instability is abrogated, and oncogenic gain-of-function properties are observed accompanied by massive accumulation of steady state mutant p53 protein levels relative to the low or undetectable steady state level of wild-type (WT) p53 in normal cells. Mutation of p53 may affect its stability through a combination of mutant p53's inherent biochemical and biophysical properties as well as pathways aberrantly activated in genetically damaged cells. The increased stability of mutant p53 proteins is key to its ability to accumulate to high levels and phenotypically exhibit "gain-of-function" properties. In this chapter we will address the multifaceted ways in which intrinsic mutant p53 properties intersect with emergent properties of cancer cells to yield the stable mutant p53 phenotype.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201195     DOI: 10.1007/978-94-017-9211-0_10

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  14 in total

1.  Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.

Authors:  Marco M Candeias; Masatoshi Hagiwara; Michiyuki Matsuda
Journal:  EMBO Rep       Date:  2016-10-04       Impact factor: 8.807

Review 2.  Neomorphic mutations create therapeutic challenges in cancer.

Authors:  V Takiar; C K M Ip; M Gao; G B Mills; L W T Cheung
Journal:  Oncogene       Date:  2016-11-14       Impact factor: 9.867

Review 3.  Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Authors:  Yoav Shetzer; Alina Molchadsky; Varda Rotter
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

4.  TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.

Authors:  Brandon-Luke L Seagle; Chia-Ping Huang Yang; Kevin H Eng; Monica Dandapani; Oluwatosin Odunsi-Akanji; Gary L Goldberg; Kunle Odunsi; Susan Band Horwitz; Shohreh Shahabi
Journal:  Gynecol Oncol       Date:  2015-05-06       Impact factor: 5.482

5.  Toward an integrated map of genetic interactions in cancer cells.

Authors:  Benedikt Rauscher; Florian Heigwer; Luisa Henkel; Thomas Hielscher; Oksana Voloshanenko; Michael Boutros
Journal:  Mol Syst Biol       Date:  2018-02-21       Impact factor: 11.429

6.  USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.

Authors:  Achuth Padmanabhan; Nicholes Candelaria; Kwong-Kwok Wong; Bryan C Nikolai; David M Lonard; Bert W O'Malley; JoAnne S Richards
Journal:  Nat Commun       Date:  2018-03-28       Impact factor: 14.919

7.  Comprehensive molecular analysis based on somatic copy number alterations in intramucosal colorectal neoplasias and early invasive colorectal cancers.

Authors:  Tamotsu Sugai; Makoto Eizuka; Wataru Habano; Yasuko Fujita; Ayaka Sato; Ryo Sugimoto; Kouki Otsuka; Eiichiro Yamamoto; Takayuki Matsumoto; Hiromu Suzuki
Journal:  Oncotarget       Date:  2018-05-01

8.  Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation.

Authors:  Alison E Meyer; Quinlan Furumo; Cary Stelloh; Alex C Minella; Sridhar Rao
Journal:  Neoplasia       Date:  2020-11       Impact factor: 5.715

9.  Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells.

Authors:  Ken Morita; Mina Noura; Chieko Tokushige; Shintaro Maeda; Hiroki Kiyose; Gengo Kashiwazaki; Junichi Taniguchi; Toshikazu Bando; Kenichi Yoshida; Toshifumi Ozaki; Hidemasa Matsuo; Seishi Ogawa; Pu Paul Liu; Tatsutoshi Nakahata; Hiroshi Sugiyama; Souichi Adachi; Yasuhiko Kamikubo
Journal:  Sci Rep       Date:  2017-11-30       Impact factor: 4.379

10.  A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer.

Authors:  Lin Fang; Qian Cheng; Jingjing Zhao; Yan Ge; Qi Zhu; Min Zhao; Jie Zhang; Qi Zhang; Liantao Li; Junjie Liu; Junnian Zheng
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.